Phenotyping characteristic of Tremelimumab plus MART1/DC patients segregated by responders (R) and non-responders (NR) independent of the time points.
dataset
posted on 2013-10-22, 03:31 authored by F. Javier Ibarrondo, Otto O. Yang, Thinle Chodon, Earl Avramis, Yohan Lee, Hooman Sazegar, Jason Jalil, Bartosz Chmielowski, Richard C. Koya, Ingrid Schmid, Jesus Gomez-Navarro, Beth D. Jamieson, Antoni Ribas, Begoña Comin-AnduixEarly activated (CD25−HLA−DR+PD1− & CD25+HLA−DR+PD1−), n = 40 (NR) to 48 (R) time points; late activated (CD25−HLA−DR+PD1+), n = 20 (NR) to 31 (R); effectors (CCR5+CD62L+CD137−), n = 20 (NR) to 31 (R); and effectors terminally differentiated (CD45+CD56+), n = 20 (NR) to 31 (R).
